{"algorithm_version": "v0.6.0", "applied_rules": {"base_min_final_score": 68.0, "min_bullish_analyses": 2, "min_confidence": 0.62, "min_final_score": 70.0, "min_liquidity_avg_volume": 750000, "regime": "mixed", "regime_score_delta": 2.0}, "benchmark": "SPY", "catalysts": ["October 13, 2026: UnitedHealth reported Q3 adjusted earnings of $4.69 per share versus an estimated $4.14, while revenue of $112.7 billion exceeded estimates.", "October 13, 2026: Management raised full-year 2026 adjusted earnings guidance to at least $20.50 per share from a prior range of $19.50-$20.00.", "UnitedHealth beat Q3 earnings estimates by $0.55 per share and topped revenue forecasts, signaling the business is recovering faster than expected.", "Management raised full-year profit guidance to at least $20.50 per share, giving investors a higher earnings floor to price in."], "company_name": "UnitedHealth Group", "conviction": "high", "data_quality": 0.875, "date": "2026-10-14", "favorable_models_count": 3, "final_confidence": 0.7660422767450987, "final_score": 74.78533333333334, "generated_at": "2026-10-14T07:30:00.004630-04:00", "horizon": "intraday", "models_answered": 3, "models_asked": 3, "quantitative_score": 51.13, "reason": null, "regulatory_warning": "This is automated, general-audience analysis published for informational purposes only. It is not a personal recommendation, not a promise of performance, and not an invitation to buy or sell any financial instrument. Every investment can lose value, and past results do not predict future ones.", "risks": ["The stock initially rose after earnings but gave back gains and closed down about 0.2%, suggesting investors may already have priced in the beat.", "Management said commercial medical-cost trends remain above its earlier expectations, with specialty-drug costs and No Surprises Act dispute awards adding pressure.", "Post-earnings price reaction has been muted so far.", "Ongoing concerns about rising medical costs could return.", "Relative volume is elevated at 2.29x normal, suggesting the good news may already be largely priced in after today's trading."], "shortfalls": [], "status": "signal", "summary": "The main next-session catalyst is a strong Q3 earnings beat and raised 2026 profit outlook, which is bullish. However, the muted post-earnings reaction and continuing medical-cost concerns could produce volatility or cap gains.", "ticker": "UNH", "timezone": "Europe/Zurich", "watchlist": []}